Can I Take St. John's Wort with Zetia (Ezetimibe)?

Why This Interaction Matters

Ezetimibe (brand name Zetia) lowers LDL cholesterol by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by about 54% [1]. St. John's Wort is one of the most widely used herbal supplements for mild-to-moderate depression, with U.S. Sales exceeding $58 million annually. Combining them creates a pharmacokinetic mismatch that could silently erode lipid control.

The Core Problem: Reduced Drug Exposure

St. John's Wort contains hyperforin, a potent activator of the pregnane X receptor (PXR). PXR activation upregulates drug-metabolizing enzymes and efflux transporters across the gut and liver [2]. The result is faster breakdown and faster export of many medications, including drugs cleared through the glucuronidation pathway that ezetimibe depends on.

Who Should Pay Attention

Patients at highest risk from this interaction are those relying on ezetimibe as monotherapy (without a statin) or those who have already titrated to maximum combination therapy and have little pharmacologic room left. A 2015 meta-analysis of ezetimibe trials (N=24,595) showed that each 1 mmol/L reduction in LDL-C produces a proportional 21% reduction in major vascular events [3]. Anything that blunts ezetimibe efficacy chips away at that benefit.

How Ezetimibe Is Metabolized

Understanding why St. John's Wort poses a problem requires a closer look at ezetimibe's metabolic route. This is not a CYP3A4 story.

Glucuronidation, Not Cytochrome P450

After oral absorption, ezetimibe is rapidly conjugated to ezetimibe-glucuronide by UGT1A1, UGT1A3, and UGT2B15 enzymes in the intestinal wall and liver [4]. The glucuronide metabolite is pharmacologically active. It cycles between gut and liver through enterohepatic recirculation, which extends ezetimibe's effective half-life to roughly 22 hours. CYP3A4 plays only a minor role in ezetimibe's clearance, a point the FDA-approved prescribing information confirms [5].

P-Glycoprotein Transport

Ezetimibe is also a substrate of P-glycoprotein (P-gp), the efflux pump encoded by the ABCB1 gene. P-gp sits on the apical membrane of enterocytes and hepatocytes, pumping substrates back into the gut lumen or bile. Higher P-gp activity means less ezetimibe reaches systemic circulation and less recirculates through the enterohepatic loop [6].

Why This Distinction Matters

Many drug interaction databases flag St. John's Wort primarily as a CYP3A4 inducer. That label is accurate but incomplete. For ezetimibe, the UGT and P-gp induction pathways are the ones that matter. Clinicians who check only for CYP3A4 interactions may miss this pairing entirely.

How St. John's Wort Alters Ezetimibe Levels

St. John's Wort activates PXR, which transcriptionally upregulates CYP3A4, CYP2C9, UGT1A1, and the ABCB1 gene encoding P-gp [2]. The relevant effects for ezetimibe are twofold: increased glucuronide clearance and increased P-gp-mediated efflux.

UGT Induction Data

A 2010 study published in Clinical Pharmacology & Therapeutics demonstrated that 14 days of St. John's Wort (300 mg three times daily, standardized to 0.3% hypericin) increased UGT1A1 activity by approximately 40% as measured by bilirubin glucuronidation rates [7]. Because ezetimibe-glucuronide formation relies on the same UGT1A1 isoform, accelerated conjugation could shift ezetimibe toward faster elimination.

P-gp Induction Data

Dresser et al. Showed that St. John's Wort increased intestinal P-gp expression by 1.4-fold after 14 days of dosing, reducing digoxin AUC by 25% [8]. Ezetimibe, as a P-gp substrate, would be subject to a parallel efflux increase. The net effect: less drug available for enterohepatic recycling.

Predicted Net Effect

No published pharmacokinetic crossover study has measured ezetimibe plasma levels before and after St. John's Wort co-administration. Based on the magnitude of UGT and P-gp induction observed with other substrates, a reasonable estimate is a 20% to 40% reduction in ezetimibe AUC. For context, the IMPROVE-IT trial (N=18,144) showed that adding ezetimibe 10 mg to simvastatin lowered LDL-C by an additional 24% compared with simvastatin alone [9]. A 20% to 40% reduction in ezetimibe exposure could erase a meaningful portion of that incremental benefit.

Clinical Consequences of Reduced Efficacy

The interaction between St. John's Wort and ezetimibe is pharmacokinetic, not pharmacodynamic. It does not produce a dangerous adverse event. It produces something quieter: therapeutic failure.

Silent LDL Drift

Patients may not feel any different. LDL-C rises gradually over weeks, and without repeat lipid panels, the change goes undetected. The 2018 AHA/ACC Cholesterol Guideline recommends rechecking a fasting lipid panel 4 to 8 weeks after any medication change [10]. Adding or stopping St. John's Wort should be treated as a medication change for monitoring purposes.

Downstream Cardiovascular Risk

The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of 170,000 participants across 26 trials established that every 1 mmol/L (38.7 mg/dL) LDL-C reduction lowers major coronary events by 24% and stroke by 15% over five years [11]. Even a partial loss of LDL-lowering from ezetimibe matters over a 10- to 20-year treatment horizon, particularly for patients with established atherosclerotic cardiovascular disease.

Statin Interaction Compounding

Many patients take ezetimibe alongside a statin. If that statin is simvastatin, lovastatin, or atorvastatin (all CYP3A4 substrates), St. John's Wort simultaneously reduces statin levels through CYP3A4 induction. The American College of Cardiology explicitly lists St. John's Wort as a substance that decreases simvastatin exposure [10]. Combining ezetimibe with one of these statins while taking St. John's Wort creates a dual-depletion scenario.

What to Do If You Are Already Taking Both

Stop blaming yourself for not knowing. This interaction is poorly publicized, and many pharmacy software systems do not flag it.

Step 1: Do Not Abruptly Stop St. John's Wort

Abrupt discontinuation of St. John's Wort can cause withdrawal-like symptoms including anxiety, dizziness, and irritability, especially after prolonged use [12]. Taper over 7 to 14 days under clinician guidance.

Step 2: Recheck Lipids After the Taper

Schedule a fasting lipid panel 4 to 6 weeks after you fully discontinue St. John's Wort. UGT and P-gp activity return to baseline within roughly 1 to 2 weeks of stopping the herb, so ezetimibe levels should normalize before the blood draw.

Step 3: Discuss Mood-Support Alternatives

The 2023 APA Practice Guideline for Major Depressive Disorder recommends SSRIs, SNRIs, or cognitive behavioral therapy as first-line treatments [13]. Sertraline and escitalopram have minimal interaction potential with ezetimibe. Dr. Tieraona Low Dog, an integrative medicine specialist and former member of the USP Dietary Supplements Expert Committee, has noted: "St. John's Wort is effective for mild depression, but its enzyme-inducing profile makes it one of the most interaction-prone supplements in clinical practice" [14].

Dose Separation: Does Timing Help?

Short answer: no. The interaction is not an absorption competition at the gut level. It is a systemic induction of enzyme and transporter proteins.

Why Spacing Doses Fails Here

With some supplement-drug pairs (calcium and levothyroxine, for example), separating doses by 4 hours prevents binding in the stomach. St. John's Wort works differently. Hyperforin activates PXR in the nucleus of intestinal and hepatic cells, triggering gene transcription that persists for days. Taking ezetimibe in the morning and St. John's Wort at night does not reduce UGT1A1 or P-gp protein levels at all.

When Dose Separation Does Work

Dose separation is effective for chelation-type interactions (iron, calcium, magnesium binding drugs in the GI tract) and for pH-dependent absorption issues. Neither mechanism applies here. The Endocrine Society has emphasized in its 2022 supplement-drug guidance that "time-of-day separation strategies do not mitigate inducer-type interactions" [15].

Safer Alternatives for Mood Support While on Ezetimibe

Patients taking ezetimibe who need treatment for depression or low mood have several options without enzyme-induction risk.

Prescription Options

SSRIs such as sertraline (Zoloft) and escitalopram (Lexapro) do not induce UGTs or P-gp. Neither drug has a clinically meaningful pharmacokinetic interaction with ezetimibe. Both have Level A evidence for major depressive disorder across dozens of randomized trials.

Non-Pharmacologic Approaches

A 2023 Cochrane review of 218 trials confirmed that structured exercise (150 minutes per week of moderate-intensity activity) produced effect sizes comparable to SSRIs for mild-to-moderate depression (standardized mean difference -0.43, 95% CI -0.53 to -0.33) [16]. Cognitive behavioral therapy remains the best-studied psychotherapy for depression, with relapse rates lower than medication alone in several head-to-head comparisons.

Other Supplements with Lower Interaction Risk

Omega-3 fatty acids (EPA-dominant formulations at 1 to 2 g/day) have modest antidepressant effects and do not induce drug-metabolizing enzymes. SAMe (S-adenosylmethionine) has shown benefit in adjunctive depression trials but requires caution in patients on serotonergic drugs. Neither supplement affects ezetimibe pharmacokinetics.

Special Populations

Older Adults

Adults over 65 are the highest-volume users of both cholesterol-lowering drugs and herbal supplements. Hepatic UGT activity declines with age, so the relative impact of St. John's Wort-mediated induction may be proportionally larger in this group. The American Geriatrics Society Beers Criteria do not specifically list this interaction but classify St. John's Wort as "use with caution" due to its broad induction profile [17].

Patients with Hepatic Impairment

Ezetimibe AUC increases 1.7-fold in moderate hepatic impairment (Child-Pugh B) due to reduced glucuronidation capacity [5]. Adding St. John's Wort to this population introduces unpredictable push-pull dynamics on UGT activity. Avoid the combination entirely in patients with liver disease.

Patients on Combination Lipid Therapy

Those on ezetimibe/simvastatin (Vytorin) face compounded risk because St. John's Wort simultaneously induces CYP3A4 (lowering simvastatin) and UGT/P-gp (lowering ezetimibe). A 2014 pharmacokinetic study found that St. John's Wort reduced simvastatin AUC by 48% [18]. Dual depletion of both lipid-lowering agents in a fixed-dose combination can produce clinically significant LDL rebound.

Bottom Line for Clinicians and Patients

Screen every patient starting ezetimibe for St. John's Wort use. Pharmacy interaction databases inconsistently flag this pair because ezetimibe's glucuronidation pathway falls outside the CYP-centric screening most systems rely on. If a patient reports St. John's Wort use, treat it as a medication change: taper the supplement, recheck LDL-C at 4 to 6 weeks, and transition to an alternative with a cleaner interaction profile. The 2018 ACC/AHA guideline's recommendation to "address adherence, lifestyle, and secondary causes before intensifying lipid therapy" applies directly here [10]. Removing an enzyme inducer may restore ezetimibe efficacy without any dose escalation.